BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38330710)

  • 1. The effect of lipid metabolism on cuproptosis-inducing cancer therapy.
    Zhong Y; Zeng W; Chen Y; Zhu X
    Biomed Pharmacother; 2024 Mar; 172():116247. PubMed ID: 38330710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper homeostasis and cuproptosis in mitochondria.
    Tian Z; Jiang S; Zhou J; Zhang W
    Life Sci; 2023 Dec; 334():122223. PubMed ID: 38084674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis: Harnessing Transition Metal for Cancer Therapy.
    Wang W; Mo W; Hang Z; Huang Y; Yi H; Sun Z; Lei A
    ACS Nano; 2023 Oct; 17(20):19581-19599. PubMed ID: 37820312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.
    Wang Y; Chen Y; Zhang J; Yang Y; Fleishman JS; Wang Y; Wang J; Chen J; Li Y; Wang H
    Drug Resist Updat; 2024 Jan; 72():101018. PubMed ID: 37979442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.
    Abdullah KM; Kaushal JB; Takkar S; Sharma G; Alsafwani ZW; Pothuraju R; Batra SK; Siddiqui JA
    Heliyon; 2024 Mar; 10(5):e27496. PubMed ID: 38486750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper homeostasis and cuproptosis in cancer immunity and therapy.
    Liu WQ; Lin WR; Yan L; Xu WH; Yang J
    Immunol Rev; 2024 Jan; 321(1):211-227. PubMed ID: 37715546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
    Zheng P; Zhou C; Lu L; Liu B; Ding Y
    J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cuproptosis, the novel therapeutic mechanism for heart failure: a narrative review.
    Yuan HJ; Xue YT; Liu Y
    Cardiovasc Diagn Ther; 2022 Oct; 12(5):681-692. PubMed ID: 36329965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles and mechanisms of copper homeostasis and cuproptosis in osteoarticular diseases.
    Han J; Luo J; Wang C; Kapilevich L; Zhang XA
    Biomed Pharmacother; 2024 May; 174():116570. PubMed ID: 38599063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.
    Feng Y; Yang Z; Wang J; Zhao H
    Cell Commun Signal; 2024 May; 22(1):249. PubMed ID: 38693584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper Deposition in Polydopamine Nanostructure to Promote Cuproptosis by Catalytically Inhibiting Copper Exporters of Tumor Cells for Cancer Immunotherapy.
    Chang J; Yin W; Zhi H; Chen S; Sun J; Zhao Y; Huang L; Xue L; Zhang X; Zhang T; Dong H; Li Y
    Small; 2024 Feb; ():e2308565. PubMed ID: 38339770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid changes and molecular mechanism inducing cuproptosis in Cryptocaryon irritans after copper-zinc alloy exposure.
    Zahid A; Abiodun OS; Xie X; Yin F
    Pestic Biochem Physiol; 2024 Feb; 199():105756. PubMed ID: 38458693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cuproptosis in cancers: Function and implications from bench to bedside.
    Huang XY; Shen JY; Huang K; Wang L; Sethi G; Ma Z
    Biomed Pharmacother; 2024 Jul; 176():116874. PubMed ID: 38850661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research progress in cuproptosis in liver cancer.
    Chen L; Liu D; Tan Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting cuproplasia and cuproptosis in cancer.
    Tang D; Kroemer G; Kang R
    Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis: mechanisms and links with cancers.
    Xie J; Yang Y; Gao Y; He J
    Mol Cancer; 2023 Mar; 22(1):46. PubMed ID: 36882769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy.
    Xu Y; Liu SY; Zeng L; Ma H; Zhang Y; Yang H; Liu Y; Fang S; Zhao J; Xu Y; Ashby CR; He Y; Dai Z; Pan Y
    Adv Mater; 2022 Oct; 34(43):e2204733. PubMed ID: 36054475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies.
    Bian C; Zheng Z; Su J; Chang S; Yu H; Bao J; Xin Y; Jiang X
    Front Pharmacol; 2023; 14():1271613. PubMed ID: 37767404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumor microenvironment-responsive core-shell tecto dendrimer nanoplatform for magnetic resonance imaging-guided and cuproptosis-promoted chemo-chemodynamic therapy.
    Ni C; Ouyang Z; Li G; Liu J; Cao X; Zheng L; Shi X; Guo R
    Acta Biomater; 2023 Jul; 164():474-486. PubMed ID: 37040813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crosstalk between ferroptosis and cuproptosis: From mechanism to potential clinical application.
    Liu N; Chen M
    Biomed Pharmacother; 2024 Feb; 171():116115. PubMed ID: 38181713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.